Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa

Promising Data In Newly Diagnosed Transplant-Eligible Patients

Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.

Big dart
Four may be better than three when targeting multiple myeloma • Source: Alamy

Sanofi's multiple myeloma drug Sarclisa has much ground to make up on Johnson & Johnson's blockbuster Darzalex but the French major will be hoping that new data in newly diagnosed transplant-eligible patients will help bridge the gap.

The company has highlighted positive data from the Phase III HD7 trial, conducted by the German-Speaking Myeloma Multicenter Group (GMMG)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category